Nearly 600,000 doses will be available in France for the 2024-2025 season, more than twice as many as last year, France Bleu and France Inter have learned.
:quality(50)/2023/07/07/64a7df4c5fe71_placeholder-36b69ec8.png)
Published
Reading time: 1 min
:quality(50)/2024/08/27/maxradiofr025541-66cdfb2a8fdb3643745151.jpg)
Beyfortus, a treatment designed to limit the risks of bronchiolitis in babies, will be available in pharmacies by Thursday, August 29 at the latest, France Bleu and France Inter learned Tuesday from the pharmaceutical group Sanofi, which is developing the treatment. Nearly 600,000 doses will be available in France for the 2024-2025 season, more than twice as many as last year. The first deliveries are underway, Sanofi told France Bleu Tuesday.
According to the pharmaceutical group, the maternity distribution campaign will take place from “September 15 in mainland France” and the treatment will be “available in town”Sanofi plans to allocate 595,000 doses to France (pharmacies and maternity hospitals) for the 2024-2025 season, more than twice the number of doses distributed in the 2023-2024 season in France.
According to a study conducted by the Pasteur Institute and the French Public Health Agency, Beyfortus prevented thousands of hospitalizations last winter in France. According to this work, Beyfortus was able to prevent hospitalization of between 3,700 and 7,800 babies.
Developed by the pharmaceutical giant Sanofi from the molecule nirsevimab, Beyfortus is a treatment that aims to limit infections by the respiratory syncytial virus (RSV), the main cause of bronchiolitis. This mainly affects infants, in whom it causes respiratory problems. It is generally not serious, but can sometimes require hospitalization.
